Neovasc, Inc.VANCOUVER and MINNEAPOLIS, Nov. 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device…
Source: news.google.com – Read more

Security News This Week: Hackers Are Posting the Claude Code Leak With Bonus Malware – WIRED
Security News This Week: Hackers Are Posting the Claude Code Leak With Bonus Malware WIRED


